Coherus BioSciences Inc
NASDAQ:CHRS

  • LAST PRICE
    2.0200
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    2.0200/ 94
  • Ask / Lots
    2.0600/ 10
  • Open / Previous Close
    2.1900 / 2.0200
  • Day Range
    2.0200
    2.2101
  • 52 Week Range
    1.4301
    8.3300
  • Volume
    879,713

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
CHRS
Coherus BioSciences Inc
247.4M
-0.8x
---
PBYI
Puma Biotechnology Inc
247.3M
10.7x
---
VYGR
Voyager Therapeutics Inc
415.4M
2.6x
---
RVNC
Revance Therapeutics Inc
381.4M
-0.9x
---
CDNA
CareDx Inc
426.1M
-2.2x
---
VNDA
Vanda Pharmaceuticals Inc
266.4M
104.0x
-37.98%
As of 2024-04-25

Company Information

Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. Its immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable an immunologic response and enhance outcomes for patients with cancer. Casdozokitug is an anti-IL-27 antibody being evaluated in two ongoing clinical studies: a Phase I/II study in advanced solid tumors and a Phase II study in hepatocellular carcinoma. CHS-114 is an ADCC-enhanced anti-CCR8 antibody in a Phase I/II study as a monotherapy in patients with advanced solid tumors. CHS-1000 is a preclinical candidate targeting immune-suppressive mechanisms via pathway ILT4. It markets LOQTORZI (toripalimab-tpzi), a next generation PD-1 inhibitor, UDENYCA (pegfilgrastim-cbqv), a biosimilar of Neulasta, and YUSIMRY (adalimumab-aqvh), a biosimilar of Humira.

Contact Information

Headquarters
C/O DENNIS M. LANFEAR 201 REDWOOD SHORES PARKWAY, SUITE 200REDWOOD CITY, CA, United States 94065
Phone
650-649-3530
Fax
302-655-5049

Executives

Chairman of the Board, President, Chief Executive Officer
Dennis Lanfear
Interim Chief Financial Officer
Bryan Mcmichael
Chief Development Officer
Theresa Lavallee
Chief Commercial Officer
Paul Reider
Lead Independent Director
Mats Wahlstrom

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$229.3M
Revenue (TTM)
$257.2M
Shares Outstanding
113.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.55
EPS
$-2.56
Book Value
$-1.72
P/E Ratio
-0.8x
Price/Sales (TTM)
0.9
Price/Cash Flow (TTM)
---
Operating Margin
-78.99%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.